证券代码：688246 证券简称：嘉和美康 公告编号：2024-038 一、本激励计划已履行的相关审议程序和信息披露情况 1、2022 年 6 月 29 日，公司第四届董事会第二次会议审议通过了《关于公 司<2022 年股票期权与限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2022 年股票期权与限制性股票激励计划实施考核管理办法>的议案》及《关 于提请股东大会授权董事会办理公司股权激励相关事宜的议案》。 2、2022 年 6 月 29 日，第四届监事会第二次会议审议通过了《关于公司<2022 年股票期权与限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年股票期权与限制性股票激励计划实施考核管理办法>的议案》及《关于核实公 司<2022 年股票期权与限制性股票激励计划首次授予部分激励对象名单>的议 案》。公司监事会对本激励计划相关事项进行核实并出具了相关核查意见。 3、2022 年 6 月 30 日至 7 月 9 日，在公司内部公示了《2022 年股票期权与 限制性股票激励计划首次授予部分激励对象名单》，对激励对象的姓名和职务进 行了公示。在公示的期限内，没有任何组织或个人提出异 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2024-035 嘉和美康（北京）科技股份有限公司 | | 日~2024 年 8 月 | | | 21 日 | | --- | --- | --- | --- | --- | | 预计回购金额 | 3,000 万元~5,000 万元 | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 累计已回购股数 | 100.4378 万股 | | | | | 累计已回购股数占总股本比 | 0.72% | | | | | 例 | | | | | | 累计已回购金额 | 3,003.8 万元 | | | | | 实际回购价格区间 | 18.93 元/股~35.00 元/股 | | | | | 回购方案首次披露日 回购方案实施期限 | 2023/8/23 2023 8 月 | 年 | 22 | | 一、 回购股份的基本情况 公司于 2023 年 8 月 22 日召开第四届董事会第十一次会议，审议通过了《关 于以集中竞价交易方式回购 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2024-034 嘉和美康（北京）科技股份有限公司 关于 2022 年股票期权与限制性股票激励计划 2024 年第二季度自主行权结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 ●本次行权数量： 嘉和美康（北京）科技股份有限公司（以下简称"公司"）2022 年股票期权与 限制性股票激励计划首次授予的股票期权第一个行权期可行权数量为 42.2236 万 份，行权期为 2023 年 9 月 15 日至 2024 年 7 月 14 日。2024 年 4 月 1 日至 2024 年 6 月 30 日期间，累计行权并完成股份过户登记数量为 2,743 股，占本次可行 权总量的 0.65%；截至 2024 年 6 月 30 日，累计行权数量与完成股份过户登记数 量为 151,356 股，占本次可行权总量的 35.85%。 嘉和美康（北京）科技股份有限公司 2022 年股票期权与限制性股票激励计 划预留授予的股票期权第一个行权期可行权数量为 5.21 ...

嘉和美康（北京）科技股份有限公司 关于以集中竞价交易方式回购股份进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688246 证券简称：嘉和美康 公告编号：2024-033 2024 年 5 月，公司通过上海证券交易所交易系统以集中竞价交易方式累计回 购股份 2,235 股，占公司总股本的比例为 0.002%，购买的最高价为 23.32 元/股、 最低价为 22.84 元/股，已支付的总金额为 51,479.24 元（不含印花税、交易佣金 等交易费用）。截至 2024 年 5 月 31 日，公司通过上海证券交易所交易系统以集中 竞价交易方式已累计回购公司股份 1,004,378 股，占公司总股本的 0.72%，回购成 交的最高价为 35.00 元/股、最低价为 18.93 元/股，已支付的资金总额为人民币 30,038,020.15 元（不含印花税、交易佣金等交易费用）。 本次回购股份符合相关法律法规的规定及公司的回购股份方案。 三、 其他事项 重要内容提示： | | 日~2024 年 8 月 | | ...

Financial Performance - The net profit attributable to the parent company for 2023 is CNY 42,497,439.19, while the consolidated undistributed profit is CNY -84,417,293.52[5] - The company will not distribute profits for 2023 due to existing undistributed losses and plans to cancel repurchased shares to enhance earnings per share[5] - The company's operating revenue for 2023 was CNY 695,175,319.22, a decrease of 3.04% compared to CNY 716,948,756.64 in 2022[23] - The net profit attributable to shareholders for 2023 was CNY 42,497,439.19, down 37.53% from CNY 68,024,427.15 in 2022[23] - The basic earnings per share for 2023 was CNY 0.31, a decline of 36.73% from CNY 0.49 in 2022[25] - The company's net cash flow from operating activities improved by CNY 116,115,977.11 compared to the previous year, although it remained negative[27] - The company’s net profit excluding non-recurring gains and losses was 35.67 million yuan, a decrease of 33.74% year-on-year[37] - The company reported a revenue of ¥695.18 million for the current period, a decrease of 3.04% compared to ¥716.95 million in the same period last year[130] - Operating costs decreased by 4.35% to ¥335.32 million from ¥350.57 million year-on-year, resulting in a gross margin of 51.76%, an increase of 0.66 percentage points[131] Audit and Compliance - A standard unqualified audit report was issued by Dahua Certified Public Accountants for the financial statements[5] - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management[5] - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7] - The company has not experienced any violations of decision-making procedures regarding external guarantees[8] Research and Development - Research and development expenses accounted for 32.72% of operating revenue, an increase of 8.01 percentage points from 24.71% in 2022[25] - The company is investing in artificial intelligence technology to develop its own large models and improve existing AI products[26] - The company applied for 40 new invention patents and received authorization for 17 patents during the reporting period, totaling 45 authorized invention patents by the end of the period[39] - The company’s total number of R&D personnel increased by 2.6% to 705 by the end of the reporting period[38] - The company has accumulated 45 authorized invention patents and 903 software copyrights in the field of medical information technology as of the end of the reporting period[114] Market Position and Strategy - The company has maintained its leading position in the electronic medical record (EMR) market for nine consecutive years, according to IDC's report on the Chinese EMR market share in 2022[49] - In the medical big data sector, the company achieved a market share of 8.8% in 2022, ranking first for the fourth consecutive year[50] - The company has over 1,600 hospital clients, including more than 600 top-tier hospitals, representing over 25% of all top-tier hospitals in China[75] - The company ranks first in the medical big data solution market in China as of 2022, according to IDC[78] - The company is focused on integrating various medical data systems to enhance the overall quality of healthcare services provided[56] Technology and Innovation - The company is focusing on enhancing its core technologies, with 30 core technologies developed, including real-time data transmission and storage technology[39] - The company has developed the Jiahe Medical Large Model, which supports nearly 20 medical tasks, improving the efficiency and quality of medical services through intelligent diagnosis and treatment processes[45] - The company is exploring the application of large model technology in healthcare scenarios, including health consultations and clinical research design[48] - The integration of new technologies such as big data, AI, cloud computing, and IoT is revolutionizing the medical information industry, enhancing efficiency and effectiveness in data management and patient care[72] Risks and Challenges - The company has detailed potential risks in the report, which investors should consider[4] - The company faces risks related to technology upgrades and potential core technology leaks, which could impact its competitive advantage and profitability[118] - The company is exposed to seasonal fluctuations in performance, with significant revenue recognition occurring in the second half of the year, particularly in Q4[120] - The company’s ability to recover accounts receivable is weak, posing risks of bad debt and cash flow deterioration[121] Employee and Management - The total number of employees in the parent company is 45[200] - The total number of employees in major subsidiaries is 2,005[200] - The combined total number of employees is 2,050[200] - The number of technical personnel is 1,677, representing approximately 81.7% of total employees[200] - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to CNY 6.061 million[187] Future Outlook - The company plans to focus on enhancing its product layout and competitive advantage by accelerating research and development projects[26] - The company is committed to developing AI-driven solutions that create a closed-loop smart medical service from pre-diagnosis to post-treatment[61] - The company is focusing on expanding its market presence through innovative product offerings and strategic partnerships in the healthcare sector[98] - The future outlook remains positive, with a focus on sustainable growth and innovation in the healthcare sector[179]

证券代码：688246 证券简称：嘉和美康 公告编号：2024-032 嘉和美康（北京）科技股份有限公司 关于 2023 年年度报告的信息披露监管问询函的回复 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）于 2024 年 5 月 14 日收到上海证券交易所科创板公司管理部下发的《关于对嘉和美康(北京)科技 股份有限公司 2023 年年度报告的信息披露监管问询函》（上证科创公函【2024】 0102 号）（以下简称"《问询函》"）。根据《问询函》的要求，公司与华泰联 合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）、大华会计 师事务所（特殊普通合伙）（以下简称"大华会计师"或"年审会计师"）、对 《问询函》所提及的事项进行了逐项核查、落实，现将《问询函》所涉及问题回 复如下。 一、对外投资 1.关于安德医智 报告期内，公司投入 1 亿元参与北京安德医智科技有限公司（以下简称安德 医智）破产重整，于 2024 年 4 月 17 日披露取得安德医智 22. ...

大华会计师事务所(特殊普通合伙) 《关于嘉和美康（北京）科技股份有限公司 2023 年年度报告的信息披露监管问询函》的回复 大华核字[2024]0011013479 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 大华会计师事务所(特殊普通合伙) 《关于嘉和美康（北京）科技股份有限公司 2023 年年度报告的信息披露监管问询函》的回复 目 录 页 次 一、 大华会计师事务所(特殊普通合伙)《关于嘉和 美康（北京）科技股份有限公司 2023 年年度 报告的信息披露监管问询函》的回复 1-39 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层[100039] 电话：86(10)58350011 传真：86(10)58350006 www.dahua-cpa.com 大华会计师事务所(特殊普通合伙) 《关于嘉和美康（北京）科技股份有限公司 2023 年年度报告的信息披露监管问询函》的回复 大华核字[2024]0011013479 号 ...

华泰联合证券有限责任公司关于 嘉和美康（北京）科技股份有限公司 2023 年年度报告的信息披露监管问询函 的核查意见 上海证券交易所： 嘉和美康（北京）科技股份有限公司（以下简称"公司"、"嘉和美康"）收 到贵所于 2024 年 5 月 14 日下发的《关于对嘉和美康（北京）科技股份有限公司 2023 年年度报告的信息披露监管问询函》（上证科创公函【2024】0102 号）（以 下简称"《问询函》"），华泰联合证券有限责任公司（以下简称"华泰联合证券"、 "保荐机构"）作为公司首次公开发行股票的保荐机构及持续督导机构，会同公 司及相关中介机构，对问询函所提及的事项进行了逐项落实，现将问询函所涉及 问题进行回复，请予审核。 一、对外投资 1.关于安德医智 报告期内，公司投入 1 亿元参与北京安德医智科技有限公司（以下简称安德 医智）破产重整，于 2024 年 4 月 17 日披露取得安德医智 22.4541%的股权并完 成股权过户。年报显示，公司参与此次破产重整，可实现与安德医智在医疗人工 智能领域的多层次合作，进一步拓展智能医学解决方案市场。请公司：（1）列示 安德医智近三年主要财务数据及资产评估情况，结合同 ...

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [2] Core Views - The company has faced performance pressure in 2023 due to the rhythm of hospital procurement, with a revenue of 695 million yuan, a year-on-year decrease of 3.04%, and a net profit of 42 million yuan, down 37.53% [5] - In Q1 2024, the company reported a revenue of 123 million yuan, a year-on-year increase of 14.00%, and significantly reduced losses compared to the same period last year [6] - The company is increasing its R&D investment, which accounted for 32.72% of revenue in 2023, up 8.01 percentage points year-on-year, enhancing its competitive advantage [7] - The company is exploring deep applications of artificial intelligence in the medical field, having developed a large medical model that supports various medical tasks [8] Financial Summary - In 2023, the company achieved a revenue of 695 million yuan, with a projected revenue of 838 million yuan in 2024, representing a year-on-year growth of 20.6% [9] - The net profit is expected to rebound significantly in 2024, reaching 111 million yuan, a year-on-year increase of 160.4% [10] - The company’s gross margin is projected to remain stable, with slight improvements expected over the next few years [9][10] R&D and Market Position - The company is focusing on the development of intelligent diagnosis and treatment technologies based on AI and big data, aligning with national policies promoting smart hospital construction [7][8] - The company has become the largest shareholder of Ande Medical Intelligence, which may enhance its capabilities in AI-assisted diagnosis and treatment decision-making [8] Earnings Forecast - The company is expected to achieve revenues of 838 million yuan in 2024, 1.015 billion yuan in 2025, and 1.244 billion yuan in 2026, with corresponding net profits of 111 million yuan, 135 million yuan, and 157 million yuan respectively [10][14]